{"altmetric_id":4803648,"counts":{"readers":{"mendeley":7,"citeulike":0,"connotea":0},"total":{"posts_count":11},"news":{"unique_users_count":1,"unique_users":["antimicrobial_agents_and_chemotherapry"],"posts_count":1},"twitter":{"unique_users_count":8,"unique_users":["ndm1bacteria","AntibioticLeeds","Somiccam","MGilchrist123","UKCPAPIN","CarlkRx","KlebsPapers","PulmCCNP"],"posts_count":10}},"selected_quotes":["ACTIVITY OF FOSFOMYCIN FOR ESBL UROPATHOGENS IN COMMUNITY AND HOSPITALIZED PATIENTS.","Activity of Fosfomycin against Extended-Spectrum-\u03b2-Lactamase-Producing Uropathogens in Patients in the Community\u2026"],"citation":{"abstract":"Few oral antibiotics exist for empiric treatment of extended-spectrum beta lactamase (ESBL) UTI. We sought to determine the activity of fosfomycin for ESBL uropathogens from patients at 3 VA facilities between 2010-2013. Among ESBL uropathogens, 21.6% were fosfomycin resistant. Klebsiella species were more likely than E. coli to be resistant (46% vs. 4%, p <.001). Fosfomycin remains active against a majority of ESBL uropathogens, although resistance among Klebsiella sp was higher than in previous reports.","altmetric_jid":"4f6fa60b3cf058f610006a6a","authors":["Katherine Linsenmeyer","Judith Strymish","Susan Weir","Gretchen Berg","Stephen Brecher","Kalpana Gupta"],"doi":"10.1128\/aac.02614-15","first_seen_on":"2015-11-25T00:05:21+00:00","funders":["niehs"],"issns":["1098-6596"],"journal":"Antimicrobial Agents and Chemotherapy","last_mentioned_on":1454332393,"links":["http:\/\/aac.asm.org\/content\/early\/2015\/11\/17\/AAC.02614-15.abstract?maxtoshow&HITS=10&hits=2&RESULTFORMAT&andorexacttitle=and&andorexacttitleabs=and&fulltext=ESBL&andorexactfulltext=and&searchid=1&usestrictdates=yes&resourcetype=HWCIT&ct&utm_source=dlvr.it&utm_medium=twitter","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26596940?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter","http:\/\/dx.doi.org\/10.1128\/AAC.02614-15","http:\/\/aac.asm.org\/content\/60\/2\/1134.abstract?maxtoshow&HITS=10&hits=6&RESULTFORMAT&andorexacttitle=and&andorexacttitleabs=and&fulltext=ESBL&andorexactfulltext=and&searchid=1&usestrictdates=yes&resourcetype=HWCIT&ct&utm_source=dlvr.it&utm_medium=twitter","http:\/\/aac.asm.org\/content\/60\/2\/1134.abstract?maxtoshow&HITS=10&hits=16&RESULTFORMAT&andorexacttitle=and&andorexacttitleabs=and&fulltext=Carbapenemase%252C%20carbapenem&andorexactfulltext=or&searchid=1&usestrictdates=yes&resourcetype=HWCIT&ct&utm_source=dlvr.it&utm_medium=twitter"],"pdf_url":"http:\/\/aac.asm.org\/content\/early\/2015\/11\/17\/AAC.02614-15.full.pdf","pmid":"26596940","pubdate":"2015-11-25T15:59:57+00:00","publisher_subjects":[{"name":"Microbiology","scheme":"era"},{"name":"Medical Microbiology","scheme":"era"},{"name":"Pharmacology And Pharmaceutical Sciences","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Pharmacology, Toxicology and Pharmaceutics"],"subjects":["drugtherapy"],"title":"Activity of Fosfomycin against Extended-Spectrum-\u03b2-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/activity-fosfomycin-against-extendedspectrum%CE%B2lactamaseproducing-uropathogens-patients-community-hosp"},"altmetric_score":{"score":14.05,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":14.05},"context_for_score":{"all":{"total_number_of_other_articles":7069916,"mean":6.2881480770247,"rank":469080,"this_scored_higher_than_pct":93,"this_scored_higher_than":6600091,"rank_type":"exact","sample_size":7069916,"percentile":93},"similar_age_3m":{"total_number_of_other_articles":282437,"mean":8.7588479868005,"rank":26325,"this_scored_higher_than_pct":90,"this_scored_higher_than":256060,"rank_type":"exact","sample_size":282437,"percentile":90},"this_journal":{"total_number_of_other_articles":5061,"mean":6.5957482213439,"rank":252,"this_scored_higher_than_pct":94,"this_scored_higher_than":4807,"rank_type":"exact","sample_size":5061,"percentile":94},"similar_age_this_journal_3m":{"total_number_of_other_articles":256,"mean":6.0497019607843,"rank":19,"this_scored_higher_than_pct":92,"this_scored_higher_than":236,"rank_type":"exact","sample_size":256,"percentile":92}}},"demographics":{"poster_types":{"member_of_the_public":5,"practitioner":2,"science_communicator":1},"users":{"twitter":{"cohorts":{"Members of the public":5,"Practitioners (doctors, other healthcare professionals)":2,"Science communicators (journalists, bloggers, editors)":1}},"mendeley":{"by_status":{"Unspecified":1,"Student  > Doctoral Student":1,"Student  > Postgraduate":1,"Student  > Master":2,"Other":1,"Student  > Bachelor":1},"by_discipline":{"Medicine and Dentistry":4,"Agricultural and Biological Sciences":2,"Unspecified":1}}},"geo":{"twitter":{"GB":2,"ES":1,"AU":1},"mendeley":{"KR":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/ndm1bacteria\/statuses\/669305639798083584","license":"gnip","citation_ids":[4803648],"posted_on":"2015-11-25T00:04:34+00:00","author":{"name":"Dave Roberts","url":"http:\/\/www.ndm1bacteria.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1294321879\/713px-EscherichiaColi_NIAID_normal.jpg","id_on_source":"ndm1bacteria","tweeter_id":"177368473","geo":{"lt":null,"ln":null},"followers":545},"tweet_id":"669305639798083584"},{"url":"http:\/\/twitter.com\/AntibioticLeeds\/statuses\/669396300690038784","license":"gnip","rt":["ndm1bacteria"],"citation_ids":[4803648],"posted_on":"2015-11-25T06:04:49+00:00","author":{"name":"Philip Howard","url":"http:\/\/nww.lhp.leedsth.nhs.uk\/antimicrobials","image":"https:\/\/pbs.twimg.com\/profile_images\/666506311757000704\/sqRxYL8O_normal.png","description":"Consultant Antimicrobial Pharmacist in Leeds. NHS Improvement AMR Project Lead. BSAC VP. All tweets are my own, and don't represent my employing organisations.","id_on_source":"AntibioticLeeds","tweeter_id":"216106495","geo":{"lt":54,"ln":-1.5,"country":"GB"},"followers":3122},"tweet_id":"669396300690038784"},{"url":"http:\/\/twitter.com\/Somiccam\/statuses\/669397884597641220","license":"gnip","rt":["ndm1bacteria"],"citation_ids":[4803648],"posted_on":"2015-11-25T06:11:07+00:00","author":{"name":"Somiccam","url":"http:\/\/www.somiccam.com","image":"https:\/\/pbs.twimg.com\/profile_images\/2289174070\/2qd83nr7alvw8ip3dhlo_normal.jpeg","description":"Sociedad de Microbiolog\u00eda Cl\u00ednica de Castilla-La Mancha","id_on_source":"Somiccam","tweeter_id":"386009065","geo":{"lt":39.5,"ln":-3,"country":"ES"},"followers":263},"tweet_id":"669397884597641220"},{"url":"http:\/\/twitter.com\/MGilchrist123\/statuses\/669402624576372736","license":"gnip","rt":["ndm1bacteria"],"citation_ids":[4803648],"posted_on":"2015-11-25T06:29:57+00:00","author":{"name":"Mark Gilchrist","url":"http:\/\/www.e-opat.com","image":"https:\/\/pbs.twimg.com\/profile_images\/849703973934292995\/1vY7yreK_normal.jpg","description":"Consultant Pharmacist ID - Imperial. Co-chair BSAC OPAT. @rpharms AMR group. Passionate about learning & improving local, national, global AMS - Views my own","id_on_source":"MGilchrist123","tweeter_id":"2328608307","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":1095},"tweet_id":"669402624576372736"},{"url":"http:\/\/twitter.com\/UKCPAPIN\/statuses\/669403829100789760","license":"gnip","rt":["ndm1bacteria"],"citation_ids":[4803648],"posted_on":"2015-11-25T06:34:44+00:00","author":{"name":"UK Pharm Infec Netwk","url":"http:\/\/ukclinicalpharmacy.org\/","image":"https:\/\/pbs.twimg.com\/profile_images\/593807738146172928\/eb1qMvUV_normal.jpg","description":"Official account for UKCPA Pharmacy Infection Network. Sharing professional activities & info. Independent views. #UKCPAPIN & #UKCPAPINJC for journal club.","id_on_source":"UKCPAPIN","tweeter_id":"3224597847","geo":{"lt":null,"ln":null},"followers":772},"tweet_id":"669403829100789760"},{"url":"http:\/\/twitter.com\/CarlkRx\/statuses\/669420976086585344","license":"gnip","rt":["ndm1bacteria"],"citation_ids":[4803648],"posted_on":"2015-11-25T07:42:52+00:00","author":{"name":"Carl Kirkpatrick","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000400609067\/b7f47498b4a26009261ccfa516f928ce_normal.jpeg","description":"Pharmacist\/Pharmacometrician\/Educator.  All opinions are my own.  RT \u2260 endorsement","id_on_source":"CarlkRx","tweeter_id":"426964310","geo":{"lt":null,"ln":null},"followers":605},"tweet_id":"669420976086585344"},{"url":"http:\/\/twitter.com\/KlebsPapers\/statuses\/669545980690194432","license":"gnip","citation_ids":[4803648],"posted_on":"2015-11-25T15:59:36+00:00","author":{"name":"Klebsiella Papers","image":"https:\/\/pbs.twimg.com\/profile_images\/626237508884377600\/wthBZBQF_normal.jpg","id_on_source":"KlebsPapers","tweeter_id":"3300043128","geo":{"lt":-37.83333,"ln":144.96667,"country":"AU"},"followers":152},"tweet_id":"669545980690194432"},{"url":"http:\/\/twitter.com\/ndm1bacteria\/statuses\/694145450551615494","license":"gnip","citation_ids":[4803648],"posted_on":"2016-02-01T13:09:06+00:00","author":{"name":"Dave Roberts","url":"http:\/\/www.ndm1bacteria.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1294321879\/713px-EscherichiaColi_NIAID_normal.jpg","id_on_source":"ndm1bacteria","tweeter_id":"177368473","geo":{"lt":null,"ln":null},"followers":545},"tweet_id":"694145450551615494"},{"url":"http:\/\/twitter.com\/ndm1bacteria\/statuses\/694145463373553664","license":"gnip","citation_ids":[4803648],"posted_on":"2016-02-01T13:09:09+00:00","author":{"name":"Dave Roberts","url":"http:\/\/www.ndm1bacteria.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1294321879\/713px-EscherichiaColi_NIAID_normal.jpg","id_on_source":"ndm1bacteria","tweeter_id":"177368473","geo":{"lt":null,"ln":null},"followers":545},"tweet_id":"694145463373553664"},{"url":"http:\/\/twitter.com\/PulmCCNP\/statuses\/694146483919024128","license":"gnip","rt":["ndm1bacteria"],"citation_ids":[4803648],"posted_on":"2016-02-01T13:13:13+00:00","author":{"name":"sciencebasedlife","image":"https:\/\/pbs.twimg.com\/profile_images\/821501322788818944\/ne9zYw8d_normal.jpg","description":"Intensivist nurse practitioner; don't call me a midlevel, physician extender, or non-physician provider. Advanced practice provider is acceptable.","id_on_source":"PulmCCNP","tweeter_id":"558001719","geo":{"lt":null,"ln":null},"followers":809},"tweet_id":"694146483919024128"}],"news":[{"title":"Activity of Fosfomycin against Extended-Spectrum-{beta}-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients [Susceptibility]","url":"http:\/\/ct.moreover.com\/?a=24281219493&p=1pl&v=1&x=xrHvywDDMN6inRud6QSFkQ","license":"public","citation_ids":[4803648],"posted_on":"2016-01-29T16:02:24+00:00","summary":"Katherine Linsenmeyer a, b, Judith Strymish a, c, Susan Weir a, b, Gretchen Berg a, b, Stephen Brecher a, b and Kalpana Gupta a, b, d a VA Boston Healthcare System, West Roxbury, Massachusetts, USA b Boston University School of Medicine\u2026","author":{"name":"Antimicrobial Agents, and Chemotherapry","url":"http:\/\/aac.asm.org\/"}}]}}